Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas

Jennifer E. Kim1, Mira A. Patel1, Antonella Mangraviti1, Eileen S. Kim1, Debebe Theodros1, Esteban Velarde2, Ann Liu1, Eric W. Sankey1, Ada Tam3, Haiying Xu4, Dimitrios Mathios1, Christopher M. Jackson1, Sarah Harris-Bookman1, Tomas Garzon-Muvdi1, Mary Sheu5, Allison M. Martin1, Betty M. Tyler1, Phuoc T. Tran2, Xiaobo Ye1, Alessandro Olivi1, Janis M. Taube4, Peter C. Burger1,4,6, Charles G. Drake6, Henry Brem1, Drew M. Pardoll6, and Michael Lim1

Abstract

Purpose: Checkpoint molecules like programmed death-1 (PD-1) and T-cell immunoglobulin mucin-3 (TIM-3) are negative immune regulators that may be upregulated in the setting of glioblastoma multiforme. Combined PD-1 blockade and stereotactic radiosurgery (SRS) have been shown to improve antitumor immunity and produce long-term survivors in a murine glioma model. However, tumor-infiltrating lymphocytes (TIL) can express multiple checkpoints, and expression of ≥2 checkpoints corresponds to a more exhausted T-cell phenotype. We investigate TIM-3 expression in a glioma model and the antitumor efficacy of TIM-3 blockade alone and in combination with anti-PD-1 and SRS.

Experimental Design: C57BL/6mice were implanted with murine glioma cell line GL261-luc2 and randomized into 8 treatment arms: (i) control, (ii) SRS, (iii) anti-PD-1 antibody, (iv) anti-TIM-3 antibody, (v) anti-PD-1 + SRS, (vi) anti-TIM-3 + SRS, (vii) anti-PD-1 + anti-TIM-3, and (viii) anti-PD-1 + anti-TIM-3 + SRS. Survival and immune activation were assessed.

Results: Dual therapy with anti-TIM-3 antibody + SRS or anti-TIM-3 + anti-PD-1 improved survival compared with anti-TIM-3 antibody alone. Triple therapy resulted in 100% overall survival (P < 0.05), a significant improvement compared with other arms. Long-term survivors demonstrated increased immune cell infiltration and activity and immune memory. Finally, positive staining for TIM-3 was detected in 7 of 8 human GBM samples.

Conclusions: This is the first preclinical investigation on the effects of dual PD-1 and TIM-3 blockade with radiation. We also demonstrate the presence of TIM-3 in human glioblastoma multiforme and provide preclinical evidence for a novel treatment combination that can potentially result in long-term glioma survival and constitutes a novel immunotherapeutic strategy for the treatment of glioblastoma multiforme. Clin Cancer Res; 23(1); 124-36. ©2016 AACR.

Introduction

Glioblastoma multiforme is the most common primary malignancy of the central nervous system (CNS) and is associated with a 14.6-month median survival with standard-of-care surgery, chemotherapy, and radiation (1, 2). Glioblastoma multiforme pathogenesis is characterized by tissue invasion, angiogenesis, local tissue hypoxia and necrosis, and evasion of the innate and adaptive antitumor immune response. Tumor-associated local and systemic immunosuppression has garnered significant interest, as recent studies have shown that glioblastoma multiforme induces tumor-infiltrating lymphocyte (TIL) anergy, recruit immunosuppressive regulatory T cells (Treg), and activate immune checkpoints (3–8). Checkpoint molecules, such as cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed death-1 (PD-1), are critical negative regulators of the immune system that protect the body from inappropriate immune activation. Several solid tumors, including glioblastoma multiforme, are protected from immunologic pressure by constitutive activity of immune checkpoint pathways (8). On the basis of these data, clinical development of antibodies that prevent checkpoint:ligand binding has proven to be a major advancement in cancer immunotherapy. Ipilimumab (anti-CTLA-4) was approved for metastatic melanoma in 2011, and approval of nivolumab...
Checkpoint blockade against murine gliomas.

That the addition of SRS would enhance the efficacy of dual checkpoint blockade has the potential to improve the antitumor immune response and result in durable immunity, and has direct implications for a clinical trial.

**Translational Relevance**

To our knowledge, this is the first preclinical investigation on the antitumor effects of TIM-3 blockade with stereotactic radiosurgery and/or anti-PD-1 in the setting of established glioma. Using a syngeneic orthotopic murine glioma model, we demonstrate that severely exhausted PD-1+ TIM-3+ lymphocytes accumulate in intracranial tumors in a time-dependent manner and that combination radiation and dual immune checkpoint blockade results in a significant increase in survival. Our study demonstrates the presence of TIM-3-expressing targets in human glioblastoma multiforme, provides preclinical evidence for a novel treatment combination that has potential to improve the antitumor immune response and result in durable immunity, and has direct implications for a clinical trial.

**Materials and Methods**

**Mice and cell lines**

Six to 8-week-old C57BL/6J wild-type female mice were maintained at the Johns Hopkins University Animal Facility. All animal experiments were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee. Orthotopic gliomas were established using GL261-Luc cells grown in DMEM (Life Technologies) + 10% FBS (Sigma-Aldrich) + 1% penicillin-streptomycin (Life Technologies) with the addition of 100 μg/mL G418 (Corning) selection media at 37°C, as described previously (3). GL261-Luc cells (130,000) in a volume of 1 μL were stereotactically injected into the left striatum as defined by the following coordinates: 2 mm posterior to the coronal suture, 2 mm lateral to the sagittal suture, and 3 mm deep to the cortical surface. Mice were randomly segregated and assigned to treatment arms, and presence of tumor was monitored by bioluminescent IVIS imaging (PerkinElmer) on posttumor implantation day 7, 14, 21, 28, and 42. Survival experiments were repeated in triplicate with 6 to 10 mice in each control or treatment arm. Animals were euthanized according to humane endpoints, including CNS disturbances, hunched posture, lethargy, weight loss, and inability to ambulate.

**Therapeutic antibodies**

Hamster mAbs against murine PD-1 were purified from hybridoma (G4) as described previously (15). Individual treatment dose was 200 μg per animal. Anti-murine TIM-3 antibodies were purchased from Bio X Cell and stored at −80°C in 1 mg/mL aliquots. Anti-TIM-3 clone RMT3-23 is a non-depleting, blocking antibody (16). Individual treatment dose was 250 μg/animal.

**Stereotactic radiation**

A Small Animal Radiation Research Platform (SARRP) was used to irradiate tumor-bearing animals in vivo experiments as described previously (3, 17, 51–52). CT imaging was used for each animal to localize the burr hole from tumor implantation. A 3-mm beam centered on the burr hole and underlying tumor was used to administer a total of 10 Gy radiation per animal at a rate of 1.9 Gy/minute. Dosimetric data were as described previously by Deng and colleagues (Supplementary Fig. S1; ref. 18).

**Immune cell isolation**

To analyze peripheral lymphocytes, blood (150 μL retro-orbital), lungs, livers, lymph nodes (brachial and inguinal), and spleens were harvested from naïve mice after transcardial perfusion with PBS. Solid organs were mechanically homogenized in RPMI medium + 10% FBS + 1% penicillin-streptomycin and filtered through a 100-μm mesh cell strainer (BD Falcon). Lymph nodes were washed and resuspended in PBS. Red blood cells were lysed from lung and spleen samples and washed with PBS. Livers were resuspended in 5 mL 70% Percoll (GE Healthcare). Percoll gradients were prepared by layering cells below 7 mL of 40% Percoll (44%70%) and centrifuged at 2,000 rpm for 20 minutes without brake at room temperature. Lymphocyte bands at the gradient interface were collected and washed with PBS.

To isolate brain-infiltrating lymphocytes (BIL), blood (150 μL) and brains were harvested after transcardial perfusion with PBS on postimplantation day 21. Blood samples were centrifuged at 1,250 rpm for 4 minutes, resuspended in ACK lysis buffer (Life Technologies), and then washed with PBS. Brains were mechanically homogenized, filtered, resuspended in 5 mL 80% Percoll, layered below 7 mL of 40% Percoll (40%80%), and centrifuged at 2,000 rpm for 20 minutes at room temperature. Cell layer at the 40%/80% interface was collected and washed with PBS. For cytokine analysis, cells were stimulated in RPMI + Cell Stimulation Cocktail plus protein transport inhibitors (eBioscience) at 37°C for 4 hours and then washed with PBS.
To isolate microglia, macrophages, and dendritic cells (DC), brains were mechanically homogenized in 70% Percoll and laid beneath 30% Percoll (30%/70% gradient) and then centrifuged and processed in the same manner as BILs.

Flow cytometry and immunophenotyping
For analysis of surface markers, lymphocytes were stained for CD3, CD4, CD8, PD-1, and TIM-3 (Supplementary Table S1 for antibody clones and dilutions), fixed in 1:3 fixation/permeabilization concentrate:diluent mixture (eBioscience) for 30 minutes, and stained for FoxP3 in permeabilization buffer. For cytokine analysis, cells were stained for CD3, CD4, and CD8, as described above, and then stained for IFNγ, IL2, IL17A, and TNFα. For analysis of antigen-presenting cells (APC), cells were pretreated with Fc block (anti-CD16/32), washed, and stained with Live/Dead Aqua. Cells were then stained for F4/80, CD45, CD11b, CD11c, PD-1, and TIM-3. Appropriate isotype controls were used and cells were acquired on the LSR II flow cytometer (BD). All FACS data were analyzed using BD FACS Diva software. Nonviable cells were excluded by forward versus side scatter analysis and Live/Dead Aqua (Invitrogen) staining.

Depletion studies
Tumor-bearing mice received intraperitoneal injections of either anti-CD4 (clone GK1.5, Bio X Cell) or anti-CD8 (clone 2.43, Bio X Cell) at 200 mg per animal on postimplantation days 4, 5, 6, 16, and 21.

Flank rechallenge
All animals that demonstrated long-term survival (100 days postimplantation) were challenged with subcutaneous right flank injection of 2 × 10^6 GL261-luc2 cells suspended in 100 ml of PBS and Geltrex basement membrane matrix (Life Technologies) in a 1:1 ratio. Four naïve mice were also injected as controls. Tumor presence was assessed by bioluminescent imaging on postrechallenge day 10. Tumor volumes were measured every 7 days, and presence was assessed by bioluminescent imaging on postrechallenge day 10. Tumor volumes were measured every 7 days, and presence was assessed by bioluminescent imaging on postrechallenge day 10.

IHC for human TIM-3
Formalin-fixed paraffin-embedded (FFPE) primary glioblastoma multiforme samples were obtained from an institutional brain tumor tissue bank authorized by the Institutional Review Board of Johns Hopkins University (Baltimore, MD). IHC for TIM-3 was performed on 8 randomly selected samples using a primary mouse anti-human mAb (clone F38-2E2, eBioscience) at a concentration 1.5 μg/mL, following an antigen retrieval of 10 minutes in citrate buffer, pH 6.0 at 120°C. A secondary anti-mouse IgG1 antibody was used at a concentration of 1.0 μg/mL. Amplification was performed using PerkinElmer biotin tyramide signal amplification and Dako streptavidin horseradish peroxidase. Signal was visualized by 3,3′-diaminobenzidine staining. All slides were reviewed by a board-certified pathologist (P.C. Burger).

Statistical analysis
Survival was analyzed by Kaplan–Meier method and compared by log-rank test. Unpaired t test was used to make comparisons between two independent groups. Comparisons between groups were presented as mean ± SEM. All data were analyzed using GraphPad Prism 6 and values of P < 0.05 were considered statistically significant.

Results
Tumor-bearing mice display a higher frequency of lymphocytes compared with naïve mice
To our knowledge, no data have been published on TIM-3–bearing immune cells in a murine glioma model. We first investigated the presence of TIM-3 in peripheral and cerebral tissues at physiologic baseline. Lungs, livers, lymph nodes, spleens, and brains were harvested from 6 naïve wild-type (non–tumor bearing) mice, and lymphocyte populations were isolated from each organ. Flow cytometric analysis demonstrated that less than 0.5% of all CD4 and CD8 T cells in each of these organs expressed TIM-3 on their surfaces (Fig. 1A and B and Supplementary Fig. S2). Notably, in the brain, only 0.23 ± 0.06% of all CD4 and 0.08 ± 0.05% of all CD8 T cells expressed TIM-3 on their cell surface.

We then harvested BILs at postimplantation days 7, 14, and 21 to investigate changes in TIM-3 expression over time in glioma-bearing mice. Compared with naïve animals, we observed a statistically significant increase in TIM-3 expression on BILs at each time point (Fig. 1C). By day 7, 5.65 ± 1.98% of all infiltrating CD4 T cells expressed TIM-3, compared with 0.23 ± 0.06% at baseline (P = 0.008). By day 14, mean frequency rose to 32 ± 3.16% (vs. day 7, P = 0.0004) and by day 21, mean frequency was 51.75 ± 2.03% (vs. day 14, P = 0.002). Infiltrating CD8 T cells demonstrated a similar trend of TIM-3 upregulation, with mean frequencies of 3.05 ± 0.05%, 18.28 ± 3.62%, and 47.60 ± 11.11% at days 7, 14, and 21, respectively (P < 0.05). Together, these data demonstrate that TIM-3+ CD4 and CD8 T cells comprise a large population of BILs in advanced murine gliomas and could potentially be targeted by anti-TIM-3–blocking antibodies.

We also examined TIM-3 expression in various myeloid-derived APCs in the brain. By gating on CD45+ cells, we were able to distinguish 4 major APC populations in the brain after tumor implantation: microglia (F4/80<sup>−</sup>CD45<sup>−</sup>CD11b<sup>+</sup>), infiltrating macrophages (F4/80<sup>−</sup>CD45<sup>−</sup>CD11c<sup>−</sup>CD11b<sup>−</sup>), myeloid DCs (F4/80<sup>−</sup>CD45<sup>−</sup>CD11c<sup>−</sup>CD11b<sup>+</sup>), and lymphoid DCs (F4/80<sup>−</sup>CD45<sup>+</sup>CD11c<sup>−</sup>CD11b<sup>−</sup>) (Supplementary Fig. S3). Microglia and infiltrating macrophages demonstrated the lowest frequencies of TIM-3 expression on day 7 after tumor implantation at 1.08 ± 0.42% and 0.98 ± 0.18%, respectively (Fig. 1D). Myeloid-derived DCs were observed to have a higher rate of TIM-3 expression at 15.18 ± 1.68% on day 7. None of these groups demonstrated a statistically significant increase in frequency by day 21. In contrast, lymphoid-derived DCs expressed TIM-3 at a rate of 11.67 ± 1.90% on day 7, with an increase to 25.14 ± 2.13% by day 21 (P = 0.001). These data suggest that only specific subsets of APCs express or upregulate TIM-3 in the setting of glioma.

Frequency of PD-1 and TIM-3 coexpression on BILs increases with time
PD-1<sup>+</sup> TIM-3<sup>+</sup> T cells have been shown to comprise a predominant fraction of BILs in various solid tumors and represent the most severely exhausted T-cell phenotype as defined by a failure to proliferate or produce cytokines such as IL2, TNF, and IFNγ (11). We hypothesized that PD-1 and TIM-3–coexpressing BILs are present in gliomas and represent a target for dual checkpoint blockade therapy. To test this hypothesis, we harvested BILs from glioma-bearing mice on day 7, 14, and
21 and assessed PD-1 and TIM-3 surface expression (Fig. 2 and Supplementary Fig. S4). We observed that on day 7, the majority of CD4 T cells, CD8 T cells, and FoxP3+ Tregs were PD-1+TIM-3+ with only 2.93 ± 1.23%, 1.83 ± 0.97%, and 2.70 ± 0.44%, respectively, coexpressing both checkpoints. However, we observed a reversal of this pattern on day 21, with rates of coexpression rising to 51.15 ± 2.01%, 46.20 ± 11.03%, and 64.30 ± 1.48% on CD4 T cell, CD8 T cell, and Tregs, respectively.

Figure 1.
TIM-3 expression on peripheral and CNS lymphocytes. In naive, non-tumor-bearing mice, less than 0.5% of all CD4+ (A) and CD8+ T cells (B) isolated from peripheral lymph nodes, lungs, livers, spleens, and brains had surface expression of TIM-3. C, Compared with naive mice, tumor-bearing mice demonstrate a progressive increase in TIM-3 expression. From days 7, 14, and 21 postimplantation, the percentage of CD4+ T cells expressing TIM-3 rose from 5.65 ± 1.98% to 32 ± 3.16% to 53.72 ± 2.03%, respectively (P < 0.05). The percentage of CD8+ T cells rose from 3.05 ± 0.05% to 18.28 ± 3.62% to 47.60 ± 11.11%, respectively (P < 0.05).

D, F4/80+CD45dimCD11b+ microglia and F4/80+CD45dimCD11c+CD11b+ brain-infiltrating macrophages demonstrate negligible TIM-3 expression on days 7 or 21. F4/80+CD45dimCD11c+CD11b+ DCs demonstrated stable, low expression of TIM-3, whereas F4/80+CD45dimCD11c+CD11b+ DCs showed a statistically significant increase by day 21. All experiments repeated in duplicate with ≥4 mice per arm. P values were determined by unpaired t-tests; *, P < 0.05. Comparisons within groups were presented as mean ± SEM.
Figure 2.
Frequency of TIM-3 and PD-1 coexpression on BILs over time. On day 7, the majority of CD8\(^+\) T cells (A) CD4\(^+\)
T cells (B), and FoxP3\(^+\)CD4\(^+\) Tregs (C) were TIM-3\(^-\)PD-1\(^-\). By day 14, the majority of effector T cells were
single positive for PD-1, whereas regulatory T cells had an equal rate of PD-1 single expression or PD-1 and
TIM-3 coexpression. By day 21, the majority of all three lymphocyte subsets were TIM-3\(^-\)PD-1\(^-\). Experiments
were run in duplicate with \(\geq 4\) mice per arm. Comparisons within groups were presented as
mean SEM.
respectively. In the intermittent period, a large peak in PD-1”TIM-3” BILs were seen. These cells could represent a precursor to PD-1”TIM-3” T cells, or a separate, transient population of exhausted T cells.

Targeting PD-1 and TIM-3 results in long-term survival

Having confirmed TIM-3 and PD-1 expression on glioma-infiltrating T cells, we hypothesized that dual blockade with anti-PD-1 and anti-TIM-3 antibody would result in longer survival compared with either monotherapy and that the addition of SRS would further improve survival as previously demonstrated with anti-PD-1 and SRS combination therapy (3). Using our in vivo mouse model, we compared monotherapy with SRS alone, anti-PD-1 alone, or anti-TIM-3 alone versus dual therapy with anti-PD1 + SRS, anti-TIM-3 + SRS, or anti-PD-1 + anti-TIM-3 versus triple therapy with anti-PD-1 + anti-TIM-3 + SRS (Fig. 3). A single dose of SRS was administered prior to anti-PD-1 to induce an inflammatory response and prime the tumor microenvironment for immune-based therapy. The timing for each treatment modality was based on a previously validated radiation administration schedule that took into consideration the rate of tumor growth and survival expectancy in our tumor model (19). TIM-3 dosing and timing was based on a treatment schedule suggested by Ngio and colleagues, which emphasized the importance of early delivery of TIM-3 antibody (20). Tumor growth was assessed on day 7 and 21 using bioluminescent IVIS imaging. We determined that neither anti-TIM-3 nor SRS alone had significant treatment effect, whereas anti-PD-1 improved median survival (33 days) compared with control (22 days, \( P < 0.0001 \)). The addition of anti-TIM-3 to SRS therapy increased median survival to 100 days \( (P = 0.017) \) compared with 27 days with SRS alone \( (P < 0.0001) \) and resulted in 63.2% long-term survival (defined as survival at 100 days postimplantation). Adding anti-TIM-3 to anti-PD-1 therapy improved median survival from 33 days (anti-PD-1 alone) to 100 days (anti-TIM-3 + anti-PD-1) and improved overall survival (OS) from 27.8% to 57.9%, respectively, although these numbers did not achieve statistical significance \( (P = 0.103) \). However, the addition of anti-TIM-3 to anti-PD-1 and SRS (triple therapy) resulted in an OS of 100% \( (P = 0.004) \).

Combination therapy improves immune profile of tumor microenvironment

To investigate the mechanisms underlying the observed treatment effects, brains were harvested on day 21 and assessed for markers of immune activation. The ratio of CD8 effector T cells versus Tregs has been correlated with treatment efficacy in several tumor models (21, 22). In our in vivo experiments, all treatment arms except anti-TIM-3 + SRS showed a statistically significant increase in CD8 T cell to FoxP3+ Treg ratio compared with control animals \( (P < 0.05; \text{Fig. 4A}) \). The highest ratio was observed in the anti-PD-1 only, anti-PD-1 and anti-TIM-3, and triple therapy treatment arms, with no significant difference among these groups. Notably, the addition of SRS to anti-TIM-3 therapy did not significantly increase this ratio. The frequency of CD4+ FoxP3+ Treg was also assessed \( (\text{Fig. 4B}) \). A significant decrease in Treg frequency was observed in all arms except anti-TIM-3 alone and anti-TIM-3 + SRS. The lowest frequencies were seen in the anti-PD-1 alone, anti-PD-1 + SRS, anti-PD-1 + anti-TIM-3, and triple therapy groups, with no significant difference among these groups. These data suggest that PD-1 blockade is the major mechanism responsible for these observed effects on BIL populations.
BIL activity and cytokine production was also assessed in each treatment arm (Fig. 4C and D). The frequency of IFNγ-producing CD4 cells was significantly increased in the triple therapy group compared with anti-TIM-3 alone \( (P = 0.04) \) and anti-PD-1 + SRS \( (P = 0.016) \). We observed a similar trend of increased rate of IFNγ-producing CD8 cells when adding TIM-3 blockade to anti-PD-1 + SRS therapy \( (P = 0.079) \); the addition of SRS to anti-TIM-3 also increased the frequency of IFNγ+TNFα+ effector T cells. We also noted a trend toward more polyfunctional CD4 and CD8 T cells in the triple therapy arms \( (\text{IFNγ}^+\text{TNFα}^+\text{or IFNγ}^+\text{TNFα}^+\text{IL17a}^+) \). Our results demonstrate a pattern of improved cytokine profile for both CD8 and CD4 T cells with the addition of anti-TIM-3 antibody (triple therapy) to anti-PD-1 + SRS.

Previous data have shown that the influx of CD8 T cells is responsible for the treatment effect of anti-PD-1 + SRS (3). To

Figure 4.

Immune analysis. A, CD8 effector to FoxP3+ T regulatory cell ratios are highest in treatment arms that include anti-PD-1. B, Dual checkpoint blockade and triple therapy show a trend toward the lowest percentage of FoxP3+ CD4 T cells. Triple therapy shows a trend toward highest mononuclear and polyclonal cytokine production by CD4 (C) and CD8 (D) T cells compared with all the other arms. Immune profiling experiments were repeated in duplicates with ≥3 mice per arm (A-D). E, CD4 T-cell depletion abrogated the treatment effect of anti-TIM-3 + SRS with no significant difference in survival between the TIM-3 only and TIM-3 + SRS(-CD4) arms. CD8 depletion [TIM-3 + SRS(-CD4)] also resulted in diminished treatment effect (0% OS) but had significantly improved survival compared with animals treated with anti-TIM-3 alone with median survival of 31.5 and 20.5 days, respectively \( (P < 0.001) \). F, CD4 and CD8 depletion also abrogated the survival benefits of triple therapy (0% OS), with median survival of 25.0 and 36.0 days, respectively. Depletion experiment was repeated in duplicate, and a representative repeat was presented, \( n = 8 \). Survival was analyzed by Kaplan-Meier method and compared by log-rank Mantel-Cox test. * \( P < 0.05 \).
better elucidate the mechanism mediating the therapeutic
efficacy of adding SRS to anti-TIM-3 antibody, we depleted
mice of CD4 of CD8 T cells before treatment (Fig. 4E). In mice
depleted of CD4 cells, the survival benefit of combination
therapy was abrogated, with no significant difference between
anti-TIM-3 alone and anti-TIM-3 + SRS. In contrast, mice
depleted of CD8 cells demonstrated a marginal improvement
in median survival compared with the TIM-3 monotherapy arm
\((P < 0.0001)\). However, the treatment response was signifi-
cantly less robust than in nondepleted animals, with a long-term
survival \((\geq 100\) days) of 0%. These data indicate that both CD4
and CD8 lymphocytes play a critical role in the observed
difference in OS between anti-TIM-3 monotherapy and anti-
TIM-3 + SRS dual therapy arms.

To demonstrate that both CD4 and CD8 T cells are required
to mediate the effects of triple therapy, we treated CD4 or CD8-
depleted mice with anti-PD-1, anti-TIM-3, and SRS (Fig. 4F).
Compared with nondepleted mice treated with anti-TIM-3
alone (median survival 20.5 days), both CD4- and CD8-
depleted mice demonstrated a marginal but statistically sig-
nificant improvement with triple therapy with 0% long-term
survival \((\geq 100\) days) but median survivals of 25 and 38 days,
respectively.

**Long-term survivors demonstrate immune memory**

Long-term survival was defined as 100 days postimplanta-
tion. “Cured” mice were tested for durable immune memory
by tumor rechallenge on day 100. Using naive mice as controls,
all surviving mice were rechallenged with injections of GL261-
Luc in the right flank. Hundred percent of the naive mice
developed flank tumors (Fig. 5A). However, none of the
long-term survivors were found to have established tumors by
day 30 after flank rechallenge, as confirmed by bioluminescent
imaging on day 10 (Fig. 5B). These survival patterns indicate
that the cured mice have long-term immunologic memory
against the GL261-Luc cells.

**Tumor-infiltrating immune cells in primary glioblastoma
multiforme express TIM-3**

TIM-3 expression in human tumors was assessed using IHC
on FFPE-embedded primary glioblastoma multiforme tissue
samples from 8 individual patients (Fig. 6). Five of the 8 samples
were positive for TIM-3 expression on perivascular or TILs. Four
of the samples were also found to have a staining pattern
consistent with positive tumor cells. Two samples demonstrat-
ed lysosomal staining in cells of unidentified type, and one
showed linear staining that was read as possible activated
microglia. These findings indicate that immune infiltrates in
human glioblastoma multiforme express TIM-3 and represent a
potential clinical target for anti-TIM-3 therapy.

**Discussion**

TIM-3 has been described as an inhibitory checkpoint mol-
ecule and a promising target for immunotherapy, but its role in
intracranial tumorigenesis has not yet been extensively char-
acterized. Here, we have shown that TIM-3 is upregulated in the
setting of glioma and that treatment with dual anti-PD-1 and
anti-TIM-3 checkpoint blockade plus SRS results in a dramatic
treatment effect. Our results suggest that targeting multiple
checkpoints may be a superior strategy for anti-glioblastoma
multiforme immunotherapy.

A recent study of clinical blood samples found that newly
diagnosed glioma patients had significantly higher levels of
TIM-3 expression on their blood leukocytes as compared with healthy controls. In addition, a higher frequency of TIM3+ CD8 T cells was positively correlated with a higher tumor grade and negatively correlated with Karnofsky scores (13). In our in vivo experiments, we isolated BILs from the brains of orthotopic glioma-bearing mice and observed a significant increase in TIM-3 expression on brain-infiltrating CD4 and CD8 cells compared to naive, non-tumor-bearing control animals.

**Anti-TIM-3 monotherapy**

Having demonstrated that TIM-3 is upregulated in our glioma model, we hypothesized that targeted blockade could restore antitumor activity and result in tumor regression in glioma-bearing mice. The results of our survival experiments showed that there was no significant difference in median and OS between animals receiving no treatment versus anti-TIM-3 monotherapy. By postimplantation day 21, the monotherapy and control groups were indistinguishable by clinical features, such as hunched posture, lethargy, and weight loss. This is not a novel finding, as several previous studies have shown that anti-TIM-3 alone has little to no therapeutic activity in several tumor models such as CT26 colon tumors (11), MCA-induced sarcomas (23), and ID8 ovarian cancer models (24).

**Anti-TIM-3 + PD-1**

Whereas anti-TIM-3 alone was insufficient for treatment response, the combination of anti-TIM-3 and anti-PD-1 antibody resulted in a significant survival benefit (0% vs. 57.9% OS). PD-1 and TIM-3–coexpressing T cells have been described as a severely incapacitated subset of BILs (11, 12, 25). The frequency of PD-1+ TIM-3+ vaccine-induced CD8 T cells was found to negatively correlate with in vivo expansion of effector lymphocytes in metastatic melanoma patients. Dual blockade with anti-PD-1 and anti-TIM-3 antibodies improved proliferation and cytokine production in vitro (12). Using multiple solid tumor models, Sakuishi and colleagues demonstrated that PD-1 and TIM-3 coexpression denotes a more severely exhausted phenotype of CD8 T cells compared with PD-1 expression alone. Dual blockade in vivo effectively restored INFγ production and controlled tumor growth (11). TIM-3 and PD-1 coexpression has also been reported on tumor-infiltrating Tregs (26), but in contrast to effector T cells, TIM-3 may function as a positive regulator on FoxP3+ Tregs and be a marker for a Treg population that is highly effective in inhibiting the T17 and TH17 immune responses (27). Our data demonstrated a clear trend toward increasing frequency of PD-1+ TIM-3+ CD8, CD4, as well as FoxP3+ T cells during the first 3 weeks after GL261-luc tumor implantation. These cells may function as a positive regulator on FoxP3+ Tregs and be a marker for a Treg population that is highly effective in inhibiting the T17 and TH17 immune responses (27). Our data demonstrated a clear trend toward increasing frequency of PD-1+ TIM-3+ CD8, CD4, as well as FoxP3+ T cells during the first 3 weeks after GL261-luc tumor implantation. These
findings suggest that upregulation of checkpoints contributed to an increasingly immunosuppressive tumor microenvironment. Rescue of this severely tolerized population of antitumor T cells with dual blockade may be an explanation for the increased survival with dual checkpoint blockade.

**Anti-TIM-3 + SRS**

Dual therapy with anti-TIM-3 and SRS also resulted in an improved survival compared with anti-TIM-3 alone (63.16% vs. 0% OS). Although the mechanism underlying the synergistic response of immunotherapy and radiation has not been completely elucidated, our *in vivo* experiments demonstrated a clear survival benefit conferred by the use of SRS with checkpoint inhibition. These findings are supported by mounting evidence in the literature that radiation can improve the efficacy of conventional chemotherapy (3) as well as targeted immunotherapies (3, 28). It has been hypothesized that the cytokidal effects of local radiation allow for tumor antigen release and subsequent activation of the innate and adaptive immune response (3, 29, 30). Radiotherapy has also been associated with the abscopal effect, that is, the immune-mediated eradication of tumors distant from the site of radiation (31, 32). Lymphodepleting whole-body radiation (WBR) has also been posited as a way to "prime" the body for subsequent checkpoint therapy, as demonstrated by Jing and colleagues in a recent study of a ST33 murine multiple myeloma model (33). Having previously shown that anti-PDL-1–mediated antitumor effect was significantly improved if administered after nonmyeloablative radiation (34), the authors reported that blocking both PD-1 and TIM-3 resulted in a significant survival benefit compared with anti-PDL-1 or anti-TIM-3 monotherapy when administered after sublethal WBR (500 cGy; ref. 33).

A single high dose of radiation (30 Gy) has also been shown to significantly improve the immune profile of CT26 colon tumors (35). Irradiated tumors were found to contain a 10-fold higher ratio of effector T cells to immunosuppressive myeloid-derived suppressor cells compared with nonirradiated tumors. However, the frequency of TIM-3 and/or PD-1 expression on T cells remained the same, suggesting that although radiation facilitates immune cell enrichment in tumors, BILs remain inactivated within the tumor microenvironment. These data are consistent with our own, supporting the hypothesis that radiation increases T-cell trafficking to the tumor, whereas anti-PD-1 and anti-TIM-3 reverse tumor-mediated BIL exhaustion, resulting in a more robust antitumor effect.

**Triple therapy**

Finally, triple therapy with anti-TIM-3, anti-PD-1, and SRS resulted in an OS of 100%. These findings suggest that the individual treatment modalities are complementary and that the multimodal activation of the immune system results in a robust antitumor response and high rates of long-term survivors. Flank rechallenge of all long-term survivors (>100 days) demonstrated that all "cured" animals could reject GL261-luc cells, implying that these mice possessed durable immune memory. This phenomenon has been previously described by Zeng and colleagues (3) in long-term survivor mice treated with anti-PD-1 + SRS. Our experiments further suggest that treatment with anti-TIM-3 does not abrogate this memory formation.

**Immune profiling**

To characterize the immune effects of each treatment, we conducted a series of flow cytometry–based analyses to compare the different treatment arms. Effector/regulatory BIL ratios have been associated with treatment efficacy and may be used as an indirect measure of antitumor activity (22, 36). Increased effector T-cell infiltration is also positively correlated with survival (37), while higher levels of Tregs negatively impact prognosis in glioblastoma multiforme patients (38). We demonstrated an overall trend toward a superior immune profile with triple therapy, as demonstrated by higher CD8:Treg ratios, lower frequency of FoxP3⁺ Tregs, and higher production of IFNγ, TNFα, and IL17a inflammatory cytokines. More specifically, we observed the highest CD8 T cell-to-Treg ratios as well as the lowest frequency of FoxP3⁺ CD4 T cells (Tregs) in the anti-PD-1 alone, anti-PD-1 + SRS, anti-PD-1 + anti-TIM-3, and triple therapy groups. There was no statistical difference between the anti-TIM-3 treatment arm and the control group, which was expected given that we did not see a difference in OS between these two arms. Adding anti-TIM-3 to anti-PD-1 similarly did not improve the effector to regulatory cell ratios.

Another measure of effector T-cell activity is proinflammatory cytokine expression, and previous studies have shown that inhibitory checkpoints, such as PD-1 and TIM-3, negatively regulate IFNγ, TNFα, and IL17a secretion (12, 39). Polyfunctional T cells (secreting two or more different cytokines) also represent a more potent and durable subset of effector lymphocytes (40, 41); therefore, check points to both PD-1 and TIM-3 demonstrated a trend toward increased IFNγ, TNFα, and IL17a production by CD4 or CD8 cells. This improvement in proinflammatory cytokine profile correlates with improved treatment effects and OS. One limitation of this experiment is the lack of a comprehensive understanding of the pro- and anti-inflammatory cytokine interactions in the tumor microenvironment, especially in the setting of radiation. Further study of the presence and levels of additional cytokines, such as TGFβ, may provide additional insights into the mechanism and limitations of our treatment strategy.

To elucidate the mechanism for tumor regression in mice that did not receive anti-PD-1 antibody, we depleted mice of CD4 or CD8 cells before treating with anti-TIM-3 and SRS. In our experiments, the survival benefit of adding SRS to TIM-3 blockade was completely abrogated by CD4 depletion, with no significant difference between median and OS between anti-TIM-3 + SRS + anti-CD4 versus anti-TIM-3 alone. CD8 depletion resulted in a partially abrogated effect, with a minimal improvement in median survival and 0% OS. Interestingly, these findings differ from those published by Zeng and colleagues for anti-PD-1 + SRS (3). Whereas CD8 depletion resulted in complete abrogation of the anti-PD-1 plus SRS antitumor activity, it appears that CD4 T cells may play a more prominent role in the anti-TIM-3 plus SRS response. Therefore, as might be expected, both populations were shown to be critical for the response to triple therapy with anti-TIM-3 + anti-PD-1 + SRS as demonstrated in our second set of depletion experiments.
Myeloid contributions
A previous study by Ngiow and colleagues defined the mechanism of TIM-3 blockade as both CD4 and IFNγ CD8 T cell mediated, with a possible role for CD11b+ host DCs (20). Our results show that while TIM-3 is expressed at very low levels on microglia and brain infiltrating macrophages, CD11c+ DCs expressed TIM-3 at a significantly higher rate. We also found that these cells could be further categorized as CD11b+ or CD11b–/low DCs. Notably, the CD11b–/low population was seen to upregulate surface TIM-3 during the first 3 weeks after tumor implantation, while the CD11b+ DCs maintained a relatively constant level of expression during this time. TIM-3’s function on APCs is not understood and the literature yields inconsistent results confounded by differences in pathology, timing, and anatomic location (43–45). For instance, Anderson and colleagues found that TIM-3 had opposing functions on the innate and adaptive immune system, such that CD11b+CD11c– DC-derived TIM-3 promoted TNFα secretion and Tc1 response in the setting of experimental autoimmune encephalomyelitis (43). Their observation that TIM-3 expression was restricted to CD11b+ DCs and not CD11b– macrophages was consistent with our own findings.

However, Chiba and colleagues reported that TIM-3 activation on tumor-infiltrating DCs suppressed the innate immune response and attenuated the efficacy of targeted immunotherapies (44). The observed CD45+CD11c–/CD11b– phenotype correlates with previous descriptions of “lymphoid DCs” (46), but the function of these particular APCs in the brain is not fully known. From a clinical standpoint, the efficacy of TIM-3 blockade has been shown to have only a minor dependence on CD11c+ DC activity (23). Therefore, the relevance and implications of TIM-3 upregulation on APCs will require further investigation.

TIM-3 expression in human glioblastoma multiforme
Human studies have previously confirmed the presence of TIM-3 in the setting of hepatocellular, cervical, colorectal, and ovarian cancers, as well as melanoma and leukemia (47–49). However, the presence of TIM-3 in human glioblastoma multiforme has not yet been clearly confirmed by IHC. A recent study by Liu and colleagues found that Gal-9 (the activating ligand for TIM-3) was expressed at increased level in glioma patients’ brain tissues as compared with noncancerous tissue from control patients (14). Furthermore, Gal-9 expression was significantly higher in grade 4 gliomas than in lower grade gliomas (grades 2–3), and levels of expression were associated with TIM-3 expression on CD4 and CD8 TILs.

In our final experiments, we found that 7 of 8 primary glioblastoma multiforme tissue samples stained positive for an anti-TIM-3 mAb stain. Five of the samples showed TIM-3–positive lymphocytes, four revealed a tumor cell staining pattern, and two were suspicious for TIM-3 positivity on microglia or other unidentified lysosome-containing immune cells. The IHC results are evidence that TIM-3 is expressed in human glioblastoma multiforme, and taken together with studies confirming Gal-9 expression on glioma tumor cells (14), these findings suggest that TIM-3 blockade may be an effective immunotherapeutic strategy in glioblastoma multiforme and provide a rationale for clinical translation of anti-TIM-3 therapies.

To our knowledge, this is the first preclinical investigation on the antitumor effects of TIM-3 blockade with SRS and/or anti-PD-1 in the setting of established glioma. Using a syngeneic orthotopic murine glioma model, we have shown that severely exhausted PD-1+ TIM-3+ BILs accumulate in intracranial tumors in a time-dependent manner and that combination radiation and dual immune checkpoint blockade results in a significant increase in survival. Our study demonstrates the presence of TIM-3–expressing targets in human glioblastoma multiforme and provides preclinical evidence for a novel treatment combination that has potential to improve the antitumor immune response and result in durable immunity. Further study in the preclinical and clinical settings will be needed to assess the utility and efficacy of this combination therapy.

Disclosure of Potential Conflicts of Interest
P.T. Tran is a consultant/advisory board member for Regeneron. J.M. Taube reports receiving commercial research grants from and is a consultant/advisory board member for Bristol-Myers Squibb. C.G. Drake reports receiving commercial research grants from Bristol-Myers Squibb; holds ownership interest (including patents) in Compugen, NexImmune, Potenza Therapeutics, and Tiziana Biotech; and is a consultant/advisory board member for AZ Mediummune, Bristol-Myers Squibb, Compugen, Genentech, Merck, Processa Therapeutics, and Tiziana. H. Brem is a consultant/advisory board member for Accelerating Combination Therapies, AescipeX, Camden Partners, Perosphere, and stemGen. M. Lim is a consultant/advisory board member for Agenus, Bristol-Myers Squibb, Merck, and Oncorous; reports receiving commercial research grants from Agenus and Bristol-Myers Squibb; and other commercial research support from Accuray, Ageron, Altor, Arbor, Bristol-Myers Squibb, Celldex, and Immunocellular.

Authors’ Contributions
Conception and design: J.E. Kim, M.A. Patel, C.M. Jackson, A.M. Martin, C.G. Drake, H. Brem, M. Lim


Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J.E. Kim, M.A. Patel, A. Mangraviti, E.S. Kim, D. Theodros, E. Velarde, A. Liu, D. Mathios, C.M. Jackson, M. Sheu, B.M. Tyler, P.T. Tran, X. Ye, A. Olivi, J.M. Taube, P.C. Burger, C.G. Drake, H. Brem, M. Lim


Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J.E. Kim, S. Harris-Bookman, A. Olivi, H. Brem, M. Lim

Study supervision: D. Mathios, X. Ye, M. Lim

Acknowledgments
We thank T. Kochel for her support in conducting immunostaining experiments and sharing materials and space; B. Francisca for providing anti-PD-1 antibodies from hybridoma; L. Blosser for flow cytometry support; and A. Bradford for scientific input.

Grant Support
This work was supported by Medical Student Research Fellowships from Howard Hughes Medical Institute (to J.E. Kim and M.A. Patel) and Bristol-Myers Squibb.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 28, 2015; revised May 1, 2016; accepted May 27, 2016; published OnlineFirst June 29, 2016.
References


